for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cellular Biomedicine Group Inc

CBMG.OQ

Latest Trade

14.90USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

10.98

 - 

25.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.90
Open
--
Volume
--
3M AVG Volume
0.74
Today's High
--
Today's Low
--
52 Week High
25.00
52 Week Low
10.98
Shares Out (MIL)
20.31
Market Cap (MIL)
304.22
Forward P/E
-6.36
Dividend (Yield %)
--

Next Event

Cellular Biomedicine Group Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Cellular Biomedicine Group Reports Q2 Loss Per Share Of $0.63

Cellular Biomedicine Group Files For Mixed Shelf Of Up To $200 Million

Cellular Biomedicine Group Reports First Quarter 2019 Results And Highlights Operational Progress

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cellular Biomedicine Group Inc

Cellular Biomedicine Group Inc. is engaged in the development of cell therapy technologies. The Company develops cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the goods manufacturing practices (GMP) laboratory. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. The Company is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases.

Industry

Biotechnology & Drugs

Contact Info

1345 Avenue of the Americas Fl 11

+1.347.9055663

http://www.cellbiomedgroup.com/

Executive Leadership

Terry A. Belmont

Chairman of the Board

Bizuo Liu

Chief Executive Officer, Interim Chief Financial Officer, Secretary

Yihong Yao

Chief Scientific Officer

Xia Meng

Head of Early Diagnosis & Intervention

Richard L. Wang

Chief Operation Officer

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.090

2017

-1.780

2018

-2.030

2019(E)

-2.343
Price To Earnings (TTM)
--
Price To Sales (TTM)
2,092.27
Price To Book (MRQ)
3.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
17.70
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-51.28
Return on Equity (TTM)
-44.13

Latest News

Novartis strikes deal with Chinese firm to make Kymriah

Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

Novartis strikes deal with Chinese firm to make Kymriah

Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

BRIEF-Cellular Biomedicine Group Enters Into Strategic Licensing And Collaboration Agreement With A Global Leader In Car-T Cell Therapy For Patients In China

* CELLULAR BIOMEDICINE GROUP ENTERS INTO STRATEGIC LICENSING AND COLLABORATION AGREEMENT WITH A GLOBAL LEADER IN CAR-T CELL THERAPY FOR PATIENTS IN CHINA

BRIEF-Cellular Biomedicine Group Qtrly Loss Per Share $0.51

* CELLULAR BIOMEDICINE GROUP REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

BRIEF-Cellular Biomedicine Announces Positive Clinical Data Of Knee Osteoarthritis China Phase I Trial

* CELLULAR BIOMEDICINE GROUP ANNOUNCES POSITIVE 48-WEEK CLINICAL DATA OF ALLOJOIN™ HUMAN ADIPOSE-DERIVED MESENCHYMAL PROGENITOR CELL (HAMPC) KNEE OSTEOARTHRITIS (KOA) CHINA PHASE I TRIAL

BRIEF-Cellular Biomedicine Group Reports Full-Year 2017 Financial Results And Recent Operational Progress

* CELLULAR BIOMEDICINE GROUP REPORTS FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

BRIEF-Cellular Biomedicine Files For Resale Of Up To 2.9 Mln Shares By Selling Stockholders

* CELLULAR BIOMEDICINE GROUP FILES FOR RESALE OF UP TO 2.9 MILLION SHARES BY SELLING STOCKHOLDERS - SEC FILING Source: (http://bit.ly/2oKEYbP) Further company coverage:

BRIEF-Cellular Biomedicine Group Announces $30.6 Mln Investment From Sailing Capital Overseas Investment

* CELLULAR BIOMEDICINE GROUP ANNOUNCES $30.6 MILLION INVESTMENT FROM SAILING CAPITAL OVERSEAS INVESTMENT LTD.

BRIEF-Cellular Biomedicine Group Says Enters Securities Purchase Agreement With Certain Investors

* CELLULAR BIOMEDICINE GROUP SAYS ON JAN 30, CO ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH CERTAIN INVESTORS - SEC FILING

BRIEF-Cellular Biomedicine Announces Plan To Configure Part Of Shanghai Facility

* CELLULAR BIOMEDICINE GROUP INC - ANNOUNCED PLAN TO CONFIGURE PART OF ITS FACILITY IN SHANGHAI WITH GE HEALTHCARE'S FLEXFACTORY PLATFORM

BRIEF-Cellular Biomedicine Group reports qtrly ‍loss per share $0.43

* Cellular Biomedicine Group reports third quarter financial results and recent operational highlights

BRIEF-Thermo Fisher Scientific and Cellular Biomedicine announce partnership to develop manufacturing processes

* Thermo Fisher Scientific and Cellular Biomedicine Group announce strategic partnership to develop manufacturing processes

BRIEF-BioLife Solutions CryoStor cell freeze media embedded in Cellular Biomedicine Group clinical trial of AlloJoin

* BioLife Solutions CryoStor cell freeze media embedded in Cellular Biomedicine Group clinical trial of AlloJoin Source text for Eikon: Further company coverage:

BRIEF-Cellular Biomedicine Q2 ‍loss per share $0.43​

* Cellular Biomedicine Group reports second quarter and first half 2017 financial results and business highlights

BRIEF-Cellular Biomedicine Group announces stock repurchase program

* Cellular Biomedicine Group (CBMG) announces stock repurchase program

BRIEF-Cellular Biomedicine adds second clinical site in the expansion of CAR-T Phase I clinical trial

* Cellular Biomedicine Group (CBMG) announces the addition of a second clinical site in the expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I clinical trial for its CARD-1 trial in patients with non-hodgkin lymphoma (NHL)

BRIEF-Cellular Biomedicine Q1 net loss per share $0.43

* Cellular Biomedicine Group reports first quarter 2017 financial results and provides business highlights

BRIEF-Cellular Biomedicine, GE Healthcare Life Sciences China established strategic research collaboration

* Cellular Biomedicine - co, GE Healthcare Life Sciences China established strategic research collaboration

BRIEF-Cellular Biomedicine had working capital of $38.3 mln as of Dec. 31

* Cellular biomedicine group reports full-year 2016 financial results and recent operational progress

BRIEF-Cellular Biomedicine reports Q3 loss per share $0.75

* Cellular Biomedicine Group reports third quarter financial results and recent operational highlights Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up